Novartis’ Exjade Label Expansion To Get Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Indication for non-transfusion dependent thalassemia, a cluster of inherited blood disorders that cause mild anemia, will be reviewed by FDA’s Oncologic Drugs Advisory Committee Nov. 8.
You may also be interested in...
CEO Interview: Novartis' Dan Vasella
Novartis has done better than most Pharmas over the past five years, though shareholders are still dissatisfied. But CEO Dan Vasella continues playing for the long-term -- pursuing R&D innovation and cost-effective dealmaking, all within a relatively conservative strategic framework.
Novartis Exjade Clears FDA As First Oral Chelating Agent
Novartis receives broad indication for deferasirox for treatment of iron overload in patients over 2 years of age.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.